The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...
UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T has the potential to treat many more cancers.
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
A new strategy strengthens the bond between the T cell and a target tumor cell, improving the cytotoxic function of the T cell.
SHANGHAI, March 19 (Reuters) - AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and an ...
Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...
A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and ...
BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...
Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results